Explore Curo’s research catalog and lot-level COAs.
Trial history and LAT8881 · Updated October 13, 2026
The AOD-9604 peptide is a synthetic, 16-amino-acid fragment modeled on the C-terminal end of human growth hormone. It went through a human obesity development program that ended in 2007 after a missed primary endpoint, later reappeared in pain studies under the name LAT8881, and is not an approved drug. Today it is a laboratory research compound.
For research materials and lot documents, explore Curo’s full research catalog or view kits for Retatrutide, GHK-Cu and KLOW.
For further reading, visit Curo Insights.
AOD-9604 is the hGH 176 to 191 sequence with tyrosine in place of the first phenylalanine, a difference of one oxygen atom.
Its largest obesity trial, METAOD006, did not meet its primary endpoint, and development for that use ended in 2007.
The same substance is registered as LAT8881 in three Lateral Pharma studies completed between 2020 and 2023.
On December 4, 2024, all 12 voting committee members opposed adding AOD-9604 free base or acetate to the 503A bulks list.
AOD-9604 is a hexadecapeptide, a chain of 16 amino acids closed into a ring by a disulfide bond between two cysteines. FDA's briefing materials describe it as a tyrosine added to the N-terminal end of a 15-amino-acid piece of human growth hormone, and list its formula as C78H123N23O23S2, its molecular weight as 1,815.1 g/mol and its CAS number as 221231-10-3. An extended research record covers the identifiers and sources in more detail.
Some catalogs list "hGH fragment 176-191", the unmodified sequence that has phenylalanine rather than tyrosine at its first position. The two molecules differ by one oxygen atom, about 16 daltons (roughly 1,815 against 1,799 g/mol), so they are separate compounds with separate identifiers. People searching for the AOD 9604 peptide also meet the spellings AOD9604 and Tyr-hGH 177-191 for the same compound.
AOD-9604's obesity development program ended in 2007 after its largest trial missed the primary endpoint. Lateral Pharma later studied the same substance as LAT8881 in neuropathic pain, acute migraine and lumbar radicular pain.
The compound came out of research at Monash University and moved into commercial development at Metabolic Pharmaceuticals. Lateral Pharma's later protocol counts six completed clinical trials with 936 participants. The last and largest, METAOD006 (the OPTIONS study in FDA's briefing), was a randomized, double-blind, placebo-controlled Phase 2b trial in 502 adults with obesity (BMI 30 to 45). It ran for 24 weeks, with a supervised diet and exercise program in every arm.
The primary efficacy endpoints were body weight after 12 weeks, plus safety and tolerability. The sponsor reported no significant difference between AOD-9604 and placebo on the body weight endpoint, and development for obesity ended in 2007. FDA reviewers wrote in December 2024 that they found no published account of the study's design or efficacy results.
Lateral Pharma Pty Ltd later sponsored the same substance as LAT8881. According to the protocol attached to the ClinicalTrials.gov record for NCT03865953, LAT8881 was previously known as AOD9604. That study was a randomized, placebo-controlled, double-blind, crossover Phase 2a trial in neuropathic pain, completed May 3, 2020. NCT04153409, a Phase 2 proof-of-concept study in acute migraine, was completed April 10, 2020. NCT05298306, a two-part Phase 1 study in lumbar radicular pain, was completed June 16, 2023.
As of October 2026, AOD-9604 is not an approved drug. FDA's Pharmacy Compounding Advisory Committee reviewed its free base and acetate forms on December 4, 2024, with obesity as the use FDA evaluated. All 12 voting members voted against placing either form on the 503A bulks list, with no abstentions, according to the committee's summary minutes. The committee advises FDA, so the vote is a recommendation.
FDA's briefing materials also describe characterization gaps for the free base, including missing data on impurities, aggregates, bioburden and bacterial endotoxins. The published July 23 and 24, 2026 committee agenda names other substances and does not include AOD-9604. An agenda is evidence of the scheduled review, rather than a complete search of every later regulatory action.
The compound stays in the literature for documented reasons. It is a defined fragment of a larger hormone, its first development program ended with a recorded primary endpoint result, and the same substance later appeared under a second name in federal registries and trial listings. Literature searches for the AOD-9604 peptide work best when they cover AOD-9604, AOD9604 and LAT8881 together.
Because the unmodified fragment differs by one oxygen atom, a laboratory has to measure which of the two it holds. A mass-spectrometry result separates 1,815 from 1,799 g/mol, while an HPLC purity percentage alone does not show which is present. A certificate of analysis is more informative when it carries the lot number from the container, the testing laboratory's name, a report identifier and the chromatogram itself. This COA batch documentation guide explains how to read those fields.
The linked Peptide Fragments & Blends catalogue does not list AOD-9604 as of October 13, 2026. A category label does not establish that a supplier carries a particular compound; check the current product entry and lot documents.
For a field-by-field check, the peptide COA guide explains how to connect a lot number, identity method and purity result.
FDA's December 2024 briefing describes AOD-9604 as an unapproved substance. On December 4, 2024, the Pharmacy Compounding Advisory Committee voted 0 yes to 12 no on including its free base and acetate forms on the 503A bulks list. The vote addresses compounding eligibility and is separate from approval of a drug product.
AOD-9604's early studies focused on safety and tolerability. Its largest obesity trial, METAOD006, did not meet the primary endpoint, and development for that use ended in 2007. Lateral Pharma later registered three studies of the same substance as LAT8881, in neuropathic pain, acute migraine and lumbar radicular pain. Completed registry status records that a study ended; it does not establish a successful efficacy result.
The unmodified hGH fragment 176-191 has phenylalanine at its first position. AOD-9604 has tyrosine there, which adds one oxygen atom and about 16 daltons (about 1,815 against 1,799 g/mol). The clinical program described on this page used AOD-9604, and the two compounds carry different registry identifiers.
Lateral Pharma Pty Ltd sponsors the same substance as LAT8881 in pain research. The protocol on ClinicalTrials.gov record NCT03865953 says the substance was previously known as AOD9604, and as of October 2026 FDA's substance registry lists LAT-8881 as the preferred name, with AOD-9604 and AOD9604 as synonyms.
Browse the current research catalogue and check the lot documents in the COA library. Catalogue materials are supplied for research use only, not human or veterinary use.